Vanda Pharmaceuticals
VNDA
172 hedge funds and large institutions have $304M invested in Vanda Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 68 increasing their positions, 55 reducing their positions, and 25 closing their positions.
354% more call options, than puts
Call options by funds: $2.18M | Put options by funds: $480K
24% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 55
12% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 25
4.41% more ownership
Funds ownership: 78.21% → 82.62% (+4.4%)
1% more funds holding
Funds holding: 171 → 172 (+1)
5% less capital invested
Capital invested by funds: $319M → $304M (-$15.3M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$12.4M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.76M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$4.12M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.27M |
| 5 |
BlackRock
New York
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EFMC
Empire Financial Management Company
New York
|
-$6.37M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$4.61M |
| 3 |
Renaissance Technologies
New York
|
-$2.08M |
| 4 |
Millennium Management
New York
|
-$1.82M |
| 5 |
Jane Street
New York
|
-$1.45M |
VNDA Hedge Fund Activity: Q2 2026 in Review
172 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2026, worth a combined $304M — down 4.8% from $319M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new VNDA positions and 25 closed out — a net gain of 3 holders — while 68 added to existing stakes and 55 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $12.4M. The largest seller was Empire Financial Management Company, exiting entirely with an estimated $6.37M sold.
- 172 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2026, up from 171 in Q1 2026.
- Funds reported $304M of Vanda Pharmaceuticals stock for Q2 2026, down 4.8% quarter-over-quarter.
- 28 funds opened new Vanda Pharmaceuticals positions in Q2 2026 and 25 closed out, a net change of +3 holders.
- The largest Vanda Pharmaceuticals buyer in Q2 2026 was AQR Capital Management, an estimated $12.4M added.
- The largest Vanda Pharmaceuticals seller in Q2 2026 was Empire Financial Management Company, an estimated $6.37M sold.
Based on aggregated 13F filings for Q2 2026.